FibroGen Inc (FGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FibroGen Inc (FGEN) has a cash flow conversion efficiency ratio of -0.106x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.85 Million) by net assets ($17.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
FibroGen Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how FibroGen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of FibroGen Inc for a breakdown of total debt and financial obligations.
FibroGen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroGen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
-0.276x |
|
MicroAlgo Inc.
NASDAQ:MLGO
|
0.006x |
|
NextTrip Inc
NASDAQ:NTRP
|
-0.316x |
|
Pharmx Technologies Ltd
AU:PHX
|
-0.559x |
|
IL&FS Engineering and Construction Company Limited
NSE:IL&FSENGG
|
0.015x |
|
Native Mineral Resources Holdings Ltd
AU:NMR
|
-0.815x |
|
Kirklands Inc
NASDAQ:KIRK
|
0.190x |
|
Farm Price Holdings Berhad
KLSE:0304
|
0.039x |
Annual Cash Flow Conversion Efficiency for FibroGen Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of FibroGen Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see FibroGen Inc (FGEN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more